Insider Selling: Cardiovascular Systems Inc. (CSII) SVP Sells 30,910 Shares of Stock
Cardiovascular Systems Inc. (NASDAQ:CSII) SVP Paul A. Koehn sold 30,910 shares of the company’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $25.07, for a total transaction of $774,913.70. Following the transaction, the senior vice president now directly owns 110,200 shares of the company’s stock, valued at approximately $2,762,714. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Cardiovascular Systems Inc. (NASDAQ:CSII) traded down 0.33% during trading on Wednesday, reaching $24.37. The company’s stock had a trading volume of 113,256 shares. The firm’s market capitalization is $812.62 million. The stock’s 50-day moving average is $24.10 and its 200 day moving average is $18.83. Cardiovascular Systems Inc. has a 52-week low of $7.50 and a 52-week high of $25.35.
Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Wednesday, August 3rd. The medical device company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Cardiovascular Systems had a negative return on equity of 38.39% and a negative net margin of 31.44%. The business earned $48.50 million during the quarter, compared to analyst estimates of $46.01 million. During the same quarter last year, the company posted ($0.27) EPS. Cardiovascular Systems’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts predict that Cardiovascular Systems Inc. will post ($0.62) EPS for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/insider-selling-cardiovascular-systems-inc-csii-svp-sells-30910-shares-of-stock.html
Several institutional investors have recently added to or reduced their stakes in the stock. Gamco Investors INC. ET AL raised its position in Cardiovascular Systems by 0.3% in the second quarter. Gamco Investors INC. ET AL now owns 36,400 shares of the medical device company’s stock worth $669,000 after buying an additional 100 shares during the period. Cutler Group LP raised its stake in shares of Cardiovascular Systems by 4.7% in the second quarter. Cutler Group LP now owns 7,787 shares of the medical device company’s stock worth $143,000 after buying an additional 350 shares during the last quarter. BlackRock Advisors LLC raised its stake in shares of Cardiovascular Systems by 3.3% in the second quarter. BlackRock Advisors LLC now owns 15,089 shares of the medical device company’s stock worth $277,000 after buying an additional 486 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Cardiovascular Systems by 39.4% in the third quarter. BNP Paribas Arbitrage SA now owns 5,445 shares of the medical device company’s stock worth $129,000 after buying an additional 1,540 shares during the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Cardiovascular Systems by 9.5% in the second quarter. California Public Employees Retirement System now owns 22,000 shares of the medical device company’s stock worth $404,000 after buying an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.
A number of research analysts have recently commented on CSII shares. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective (up previously from $20.00) on shares of Cardiovascular Systems in a research note on Wednesday, June 29th. Zacks Investment Research raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Monday, July 4th. Bank of America Corp. raised shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research report on Thursday, August 4th. Leerink Swann raised shares of Cardiovascular Systems from a “market perform” rating to an “outperform” rating and set a $30.00 target price for the company in a research report on Monday, August 22nd. Finally, JMP Securities started coverage on shares of Cardiovascular Systems in a research report on Friday, October 7th. They set an “outperform” rating and a $35.00 target price for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $27.40.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.